IngentaConnect Platelet CD62 expression and PDGFAB secretion in patients undergo...

Authors: Graff, J.¹; Andries, D.¹; Elsner, M.²; Westrup, D.³; Bassus, S.⁴; Franz, N.¹; Klinkhardt, U.¹; Harder, S.¹

Source: British Journal of Clinical Pharmacology, Volume 51, Number 6, June 2001 , pp. 577-582(6)

Abstract:

Aims

To investigate a correlation of the platelet activation marker CD62 and secretion of the growth factor PDGF from platelets in coronary patients under therapy with the GPIIb/IIIa-inhibitor abciximab. Methods

Flow cytometric assessment of fibrinogen binding (GPIIb/IIIa-binding site) and CD62 expression, as well as PDGF release of human platelets (immunoassay) and platelet aggregation with 20 µmADP and 2 µg ml⁻¹ collagen were evaluated in nine patients with stable coronary artery disease. Patients were undergoing elective balloon angioplasty and were treated with aspirin (100 mg day⁻¹), heparin (ACT < 220 s) and abciximab (bolus and infusion over 12 h). Blood samples were obtained before initiation of abciximab therapy (under aspirin and heparin) (I), 3 h after angioplasty under abciximab (II) and 12 h after termination of abciximab infusion (III). Results

Compared with sample I before abciximab therapy, fibrinogen binding was reduced to 37% (± 34 s.d., P < 0.05) (II) and 55% (± 40 s.d., P < 0.05) (III). Reduced fibrinogen binding also led to a significant reduction of the aggregation response to ADP (down to 37% ± 20) and collagen (down to 0%). Mean fluorescence intensity of CD62-expression was 78 units (± 20 s.d.) (I), 72 units (± 14 s.d.) (II) and 64 units (± 12 s.d., P < 0.05) (III). PDGF release from isolated, washed platelets was 99 (± 33 s.d.) ng/10⁹ platelets at (I), 82 (± 31 s.d.) ng/10⁹ platelets and 96 (± 30 s.d.) ng/10⁹ platelets. Conclusions

The results indicate that despite a strong reduction of GPIIb/IIIa-binding and platelet aggregation, CD62 as a marker of platelet secretion and the secretion product PDGF were only slightly reduced under abciximab treatment. No direct correlation between CD62 expression and PDGF release could be demonstrated.

Keywords: abciximab; P-selectin; platelet derived growth factor

Document Type: Research article

DOI: 10.1046/j.1365-2125.2001.01392.x

Affiliations: 1: Institute of Clinical Pharmacology, 2: Department of Cardiology, 3: Deutsche Klinik für Diagnostik, Wiesbaden, Germany 4: Center for Physiology, Medical School of the J.W. Goethe University, Frankfurt am Main and

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab

Platelet CD62 expression and PDGF_AB secretion in patients undergoing PTCA and treatment with abciximab